The fourth quarter got off to an active start this week as six of seven deals on the calendar priced. The trend of pricing pressure continued in October’s first week as four of six deals priced at the low end or below their range. Since July 25, 18 of 26...read more
Regulus Therapeutics, an early stage biotech developing microRNAs treatments for multiple serious diseases, raised $45 million by offering 11.3 million shares at $4 per share. The company, which was previously expecting to raise $50 million by offering 4.5...read more
Regulus Therapeutics, a biopharmaceutical company focused on developing drugs that target microRNA, announced terms for its IPO on Friday. The San Diego, CA-based company plans to raise $50 million by offering 4.5 million shares at a price range of $10.00 to $12...read more
Active week for IPOs marred by lackluster trading
The fourth quarter got off to an active start this week as six of seven deals on the calendar priced. The trend of pricing pressure continued in October’s first week as four of six deals priced at the low end or below their range. Since July 25, 18 of 26...read more
Regulus Therapeutics prices IPO at $4.00 as expected
Regulus Therapeutics, an early stage biotech developing microRNAs treatments for multiple serious diseases, raised $45 million by offering 11.3 million shares at $4 per share. The company, which was previously expecting to raise $50 million by offering 4.5...read more
8 US IPOs planned for the week of Oct 1
The following IPOs are expected to price this week: Berry Plastics Group (BERY), which manufactures plastic goods and containers for consumer applications, plans to raise...read more
Regulus Therapeutics sets terms for $50 million IPO
Regulus Therapeutics, a biopharmaceutical company focused on developing drugs that target microRNA, announced terms for its IPO on Friday. The San Diego, CA-based company plans to raise $50 million by offering 4.5 million shares at a price range of $10.00 to $12...read more